Clinical trial · Interventional
Evaluation of Medical Practice in the Management of Bone Metastases After Injectable Bone Antiresorptive Treatment, and Its Influence on Quality of Life
NCT02839291CI-TRIAL-00084110PRISMactive not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the current medical practice and its influence on health-related quality of life, in patients who are treated with injectable bone antiresorptive drugs (biphosphonates or denosumab) for at least one year.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Tumor With Bone Metastasis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| intravenous or oral bone antiresorptive treatments | Drug | — | UNRESOLVED |
| quality of life questionaries | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- quality of life questionaries
- description
- Patients should complete 3 quality of life questionaries (EORTC-QLQ C30 ; EORTC QLQ-BM22 and Euroqol EQ-5D) at many time points : at inclusion, every 3 months and at the end of study visit (2 years after inclusion)
- interventionNames
- Other: quality of life questionaries
- Drug: intravenous or oral bone antiresorptive treatments
Primary outcomes (1)
- measure
- evaluation of 4 targeted dimensions of the EORTC-QLQ-BM22 quality of life questionarie
- timeFrame
- to 6 months
- description
- evaluation of 4 parameters: painful sites characteristics of pain, functional impairment, psychosocial aspect
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with histologically proven tumor with bone metastasis, single or multiple (with or without metastasis extra-osseous) * Patients treated with injectable bone antiresorptive therapy for 12 months or more * Signed written informed consent Exclusion Criteria: * patient with any medical or psychiatric condition or disease which would make the patient inappropriate to complete quality of life questionaries * patient under guardianship, curator or under the protection of justice, pregnant or breast-feeding women
References
Publications (0)
Data not yet available
No reference posted for this study.